Guang-Yu Liu
Overview
Explore the profile of Guang-Yu Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wu S, Li J, Zhang Y, Wu H, Mo M, Hu N, et al.
Br J Surg
. 2023 May;
110(10):1264-1266.
PMID: 37252942
No abstract available.
12.
Wu S, Li J, Wang Y, Jin K, Yang B, Li J, et al.
Int J Surg
. 2023 May;
109(7):1863-1870.
PMID: 37132193
Background: Targeted axillary dissection (TAD) includes biopsy of clipped lymph node and sentinel lymph nodes. However, clinical evidence regarding clinical feasibility and oncological safety of non-radioactive TAD in a real-world...
13.
Gong Y, Zuo H, Zhou Y, Yu K, Liu G, Di G, et al.
Ann Transl Med
. 2023 Apr;
11(6):243.
PMID: 37082658
Background: According to preclinical experiments, mannose-sensitive hemagglutinin (PA-MSHA) exerts antiproliferative effects against breast cancer cells. It has been approved by the State Food and Drug Administration in China for complementary...
14.
Liu Y, Zhu X, Xiao Y, Wu S, Zuo W, Yu Q, et al.
Cell Res
. 2023 Mar;
33(5):389-402.
PMID: 36973538
Triple-negative breast cancer (TNBC) is a heterogeneous disease and lacks effective treatment. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. Here, we report the final results...
15.
Wu H, Luo Z, He Z, Gong Y, Mo M, Ming W, et al.
Br J Cancer
. 2023 Jan;
128(4):704.
PMID: 36717677
No abstract available.
16.
Wu H, Luo Z, He Z, Gong Y, Mo M, Ming W, et al.
Br J Cancer
. 2022 Dec;
128(4):638-646.
PMID: 36564566
Background: The OlympiA trial demonstrated the benefits of adjuvant usage of olaparib for high-risk patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) and germline BRCA (gBRCA)...
17.
Fu M, He L, Lyu J, Xi J, Liu G, Xie Y
Zhongguo Zhong Yao Za Zhi
. 2022 Dec;
47(19):5365-5374.
PMID: 36472044
This study aims to assess the efficacy and safety of Hulisan Capsules in the treatment of knee osteoarthritis, which is expected to serve as a reference for clinical practice. To...
18.
Qu F, Lin C, Liu Z, Cao A, Wu J, Liu G, et al.
Breast Cancer Res Treat
. 2022 Aug;
196(1):97-109.
PMID: 36040640
Purpose: Salvage mastectomy is traditionally recommended for patients who developed ipsilateral breast tumor recurrence (IBTR) in light of previous breast irradiation. However, it remains controversial whether surgical axillary staging (SAS)...
19.
Wu S, Li J, Wu H, Shao Z, Liu G, Hu N
Br J Surg
. 2022 Aug;
109(12):1194-1197.
PMID: 36018290
No abstract available.
20.
Yang F, Sun R, Hou Z, Zhang F, Xiao Y, Yang Y, et al.
Clin Transl Med
. 2022 May;
12(5):e825.
PMID: 35522895
Aims: MORC family CW-type zinc finger 2 (MORC2), a GHKL-type ATPase, is aberrantly upregulated in multiple types of human tumors with profound effects on cancer aggressiveness, therapeutic resistance, and clinical...